Limitation of infarct size by myocardial ischemic preconditioning

  • D. M. Van Winkle
Conference paper

Abstract

Myocardial ischemic preconditioning (IP) has caught the attention and imagination of researchers throughout the world (7). And for good reason: the magnitude of protection against ischemic injury conferred by IP is tremendous, far surpassing that offered by past pharmacological therapies. Although the original description of IP focused on limitation of myocardial infarction following acute coronary occlusion and reperfusion, IP may also decrease the incidence of ischemia-induced arrhythmias and improve post-ischemic cardiac function. However, in this article the discussion will be confined to the infarctlimiting effect of IP. Upon suffering a brief episode of ischemia, the myocardium instigates some change in itself which protects it from subsequent ischemic events. On an organ level the visible end-point is a decrease in infarct. This grossly visible change is the result of the cellular transduction of a signal and the institution of an adaptive cellular modification. But what precisely is that cellular process?

Key words

Ischemia-reperfusion myocardial infarction adenosine ATP-sensitive potassium channels protein kinase C 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Casnellic JE (1991) In: August JT, Anders MW, Murad F (eds) Protein kinase inhibitors: probes for the functions of protein phosphorylation. Advances in Pharmacology, Volume 22. Academic Press, Inc., San Diego, pp 167–205Google Scholar
  2. 2.
    Downey JM, Cohen MV, Ytrehus K, Liu Y (1994) Cellular mechanisms in ischemic preconditioning: The role of adenosine and protein kinase C. Ann NY Acad Sci 723: 82–98PubMedCrossRefGoogle Scholar
  3. 3.
    Gross GJ (1995) ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 90: 85–88PubMedCrossRefGoogle Scholar
  4. 4.
    Harding EA, Jaggar JH, Squires PE, Dunne MJ (1994) Polymyxin B has multiple blocking actions on the ATP-sensitive potassium channel in insulin-secreting cells. Pflügers Arch 426: 31–39PubMedCrossRefGoogle Scholar
  5. 5.
    Kitakaze M, Hon M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Hori H, Inoue M, Kamada T (1994) Alpha i-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5’-nucleotidase activity. J Clin Invest 95: 2197–2205CrossRefGoogle Scholar
  6. 6.
    Liu Y, Tsuchida A, Cohen MV, Downey JM (1995) Pretreatment with Angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 27: 883–892PubMedCrossRefGoogle Scholar
  7. 7.
    Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136PubMedCrossRefGoogle Scholar
  8. 8.
    Sakamoto J, Miura T, Goto M, Iimura O (1995) Limitation of myocardial infarct size by adenosine Al receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 29: 682–688PubMedGoogle Scholar
  9. 9.
    Steinberg SF, Goldberg M, Rybin VO (1995) Protein kinase C isoform diversity in the heart. J Mol Cell Cardiol 27: 141–153PubMedCrossRefGoogle Scholar
  10. 10.
    Strasser RH, Braun-Dullaeus R. Walendzik H, Marquetant R (1992) α1Receptor-independent activation of protein kinase C in acute myocardial ischemia. Mechanisms for sensitization of the adenylyl cyclase system. Cire Res 70: 1304–1312CrossRefGoogle Scholar
  11. 11.
    Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF (1994) Cardioprotection provided by adenosine receptor activation is abolished by blockade of the ATP-sensitive potassium channel. Am J Physiol 266: H829–H839PubMedGoogle Scholar
  12. 12.
    Van Winkle DM. Kuzume K, Dote K. Wolff RA (1995) Infarct limitation by protein kinase C (PKC) is attenuated by blockade of ATP-sensitive potassium channels. J Mol Cell Cardiol 27: A142 (Abstract)Google Scholar
  13. 13.
    Wall TM, Sheehy R, Hartman JC (1994) Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270: 681–688PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 1996

Authors and Affiliations

  • D. M. Van Winkle
    • 1
  1. 1.Department of Anesthesiology (UHS-2)Oregon Health Sciences UniversityPortlandUSA

Personalised recommendations